<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Cancer</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Second CRL for Replimune’s RP-1 for melanoma </title>
      <description>
        <![CDATA[Replimune Group Inc. received another complete response letter (CRL) from the U.S. FDA for immunotherapy vusolimogene oderparepvec to treat advanced melanoma, sending shares plunging by more than 19% on the April 10 PDUFA date.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730363</guid>
      <pubDate>Fri, 10 Apr 2026 17:01:36 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730363-second-crl-for-replimunes-rp-1-for-melanoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Melanoma-skin-cancer-check-dermatologist.webp?t=1743779170" type="image/jpeg" medium="image" fileSize="151014">
        <media:title type="plain">Photo of magnifying glass inspecting moles on person's back</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA accepts Telix’s resubmitted NDA for brain imaging agent </title>
      <description>
        <![CDATA[The U.S. FDA has accepted for review Telix Pharmaceuticals Ltd’s resubmitted NDA for TLX101-Px (Pixclara, 18F-floretyrosine, 18F-FET), its radiolabeled glioma imaging product for characterizing progressive or recurrent glioma in adult and pediatric patients. The FDA assigned a Sept. 11, 2026, PDUFA date.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730225</guid>
      <pubDate>Fri, 10 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730225-fda-accepts-telixs-resubmitted-nda-for-brain-imaging-agent</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Brain-scans.webp?t=1720729793" type="image/jpeg" medium="image" fileSize="203914">
        <media:title type="plain">Brain scans</media:title>
      </media:content>
    </item>
    <item>
      <title>Oricell raises $110M in pre-IPO round to advance solid tumor CAR Ts</title>
      <description>
        <![CDATA[Oricell Therapeutics Holdings Ltd closed a $110 million pre-IPO round to expand its global footprint and advance its lead candidate, a GPC3-targeted autologous CAR T therapy for liver cancer to registrational trials.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730221</guid>
      <pubDate>Fri, 10 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730221-oricell-raises-110m-in-pre-ipo-round-to-advance-solid-tumor-car-ts</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-anatomy-on-medical-background.webp?t=1775850555" type="image/jpeg" medium="image" fileSize="591366">
        <media:title type="plain">Liver anatomy on medical background</media:title>
      </media:content>
    </item>
    <item>
      <title>Biologics in development outnumber small molecules for the first time</title>
      <description>
        <![CDATA[More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline. At the start of the biotech industry, progress was slow. Between 1983 and 1995, the U.S. FDA approved an average of two biologics each year. Now, biologics have taken the lead by the smallest of margins, accounting for 50.1% of drugs in development at the start of 2026, according to the <em>Pharma Annual Review 2026</em>, published by Pharmaprojects, a firm that tracks global pharma R&D.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730343</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730343-biologics-in-development-outnumber-small-molecules-for-the-first-time</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration1.webp?t=1600982220" type="image/png" medium="image" fileSize="443224">
        <media:title type="plain">Drug research illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>New TRPC6/7 antagonists disclosed in Nyrada patent</title>
      <description>
        <![CDATA[Nyrada Pty Ltd. has synthesized new short transient receptor potential channel 6 (TRPC6) and 7 (TRPC7) antagonists potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730273</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730273-new-trpc6-7-antagonists-disclosed-in-nyrada-patent</link>
    </item>
    <item>
      <title>Aurigene Oncology and Olema Pharmaceuticals patent KAT6A degradation inducers</title>
      <description>
        <![CDATA[Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase CBL-B (CBLB)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety. They are described as potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730272</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730272-aurigene-oncology-and-olema-pharmaceuticals-patent-kat6a-degradation-inducers</link>
    </item>
    <item>
      <title>Avelos Therapeutics synthesizes new POLθ inhibitors</title>
      <description>
        <![CDATA[Avelos Therapeutics Inc. has divulged new sulfur or selenium-containing compounds acting as DNA polymerase θ (POLθ; POLQ) inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730271</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730271-avelos-therapeutics-synthesizes-new-pol-inhibitors</link>
    </item>
    <item>
      <title>Purdue Research Foundation identifies MAP3K7 inhibitors</title>
      <description>
        <![CDATA[A Purdue Research Foundation patent details the discovery of 5/5-5/6 bisaryl compounds acting as mitogen-activated protein kinase kinase kinase 7 (MAP3K7; TAK1) inhibitors reported to be useful for the treatment of multiple myeloma and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730270</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730270-purdue-research-foundation-identifies-map3k7-inhibitors</link>
    </item>
    <item>
      <title>Beone reports new GTPase KRAS inhibitors</title>
      <description>
        <![CDATA[Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. have identified new macrocyclic GTPase KRAS inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730269</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730269-beone-reports-new-gtpase-kras-inhibitors</link>
    </item>
    <item>
      <title>GALNT1 is potential therapeutic target in breast cancer</title>
      <description>
        <![CDATA[In a recent study published in the <em>Journal of Cancer Research and Clinical Oncology</em>, researchers from The First Affiliated Hospital of Guangxi Medical University and The First People’s Hospital of Qinzhou (China) investigated the expression pattern, molecular mechanisms and clinical relevance of GALNT1 in breast cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730264</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730264-galnt1-is-potential-therapeutic-target-in-breast-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NCI-Breast-Tumor-Microenvironment.webp?t=1682687608" type="image/jpeg" medium="image" fileSize="745805">
        <media:title type="plain">Breast cancer tumor and its microenvironment obtained from a live mouse model.</media:title>
        <media:description type="plain">This image of a breast cancer tumor and its microenvironment was obtained from a live mouse model using multiphoton microscopy and endogenous fluorescence. Tumor cells display in cyan, macrophages in red, collagen fibers in green. Credit: Joseph Szulczewski, David Inman, Kevin Eliceiri and Patricia Keely, Carbone Cancer Center, University of Wisconsin/National Cancer Institute, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Gilead exercises option to license Kymera’s KT-200</title>
      <description>
        <![CDATA[Gilead Sciences Inc. has exercised its option to exclusively license KT-200, a first-in-class, oral CDK2 molecular glue degrader development candidate discovered and characterized by Kymera Therapeutics Inc. under the parties’ strategic collaboration agreement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730259</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730259-gilead-exercises-option-to-license-kymeras-kt-200</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-merger-money-lightbulb.webp?t=1588286368" type="image/png" medium="image" fileSize="65086">
        <media:title type="plain">Handshake, businessmen holding dollar sign, lightbulb</media:title>
      </media:content>
    </item>
    <item>
      <title>Biologics in development outnumber small molecules for the first time</title>
      <description>
        <![CDATA[More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730211</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730211-biologics-in-development-outnumber-small-molecules-for-the-first-time</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration1.webp?t=1600982220" type="image/png" medium="image" fileSize="443224">
        <media:title type="plain">Drug research illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>C4 yourself: $1B second Roche deal evidence of DAC faith</title>
      <description>
        <![CDATA[C4 Therapeutics Inc.’s degrader-antibody conjugate (DAC) strategy gathered more steam with a new collaboration between the firm and Roche AG that brings $20 million up front with the potential for more than $1 billion in discovery, regulatory and commercial milestone payments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730207</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730207-c4-yourself-1b-second-roche-deal-evidence-of-dac-faith</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Antibody-drug-conjugate.webp?t=1632171505" type="image/png" medium="image" fileSize="395059">
        <media:title type="plain">Antibody-drug conjugate</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA says no to partial 510(k) exemption for some AI devices</title>
      <description>
        <![CDATA[In a decision that maintains the regulatory status quo, the U.S. FDA denied a petition from Harrison.ai to partially exempt certain diagnostic/detection AI devices from premarket review so long as the manufacturer has 510(k) clearance for a device in a similar category and a robust postmarket plan.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730154</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730154-fda-says-no-to-partial-510k-exemption-for-some-ai-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-concept-art.webp?t=1768944356" type="image/jpeg" medium="image" fileSize="1408746">
        <media:title type="plain">Artificial intelligence (AI), machine learning concept art</media:title>
      </media:content>
    </item>
    <item>
      <title>Sidewinder’s bispecific ADC approach draws $137M series B</title>
      <description>
        <![CDATA[Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730275</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730275-sidewinders-bispecific-adc-approach-draws-137m-series-b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-digital-dollar-sign.webp?t=1775054521" type="image/jpeg" medium="image" fileSize="639573">
        <media:title type="plain">Blue digital dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>PD-1/PD-1L interaction inhibitors described in Affirma Biotech patent</title>
      <description>
        <![CDATA[Affirma Biotech SL has disclosed new programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors potentially useful for the treatment of cancer, bacterial, fungal and viral infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730253</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730253-pd-1-pd-1l-interaction-inhibitors-described-in-affirma-biotech-patent</link>
    </item>
    <item>
      <title>Ewha Womans University, Gachon University patent YAP1/TEAD interaction inhibitors</title>
      <description>
        <![CDATA[Ewha Womans University and Gachon University have discovered new pyrazinocarbazole derivatives acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors potentially useful for the treatment of colorectal cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730251</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730251-ewha-womans-university-gachon-university-patent-yap1-tead-interaction-inhibitors</link>
    </item>
    <item>
      <title>Blossomhill Therapeutics reports new macrocyclic compounds</title>
      <description>
        <![CDATA[Blossomhill Therapeutics Inc. has identified new macrocyclic compounds potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730249</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730249-blossomhill-therapeutics-reports-new-macrocyclic-compounds</link>
    </item>
    <item>
      <title>Selective CBL-B inhibitor with improved safety profile disclosed</title>
      <description>
        <![CDATA[CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune responses. In cancer, however, this inhibitory role can impair the immune system’s capacity to detect and eradicate tumor cells. Researchers from Genentech Inc. presented the design and optimization of a series of CBL-B-targeting molecular glues.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730243</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730243-selective-cbl-b-inhibitor-with-improved-safety-profile-disclosed</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Targeted-cancer-cell.webp?t=1748961673" type="image/jpeg" medium="image" fileSize="966728">
        <media:title type="plain">Cancer cell in the cross-hairs</media:title>
      </media:content>
    </item>
    <item>
      <title>KIAA1429-MYC axis is potential target in clear cell kidney cancer</title>
      <description>
        <![CDATA[The <em>N</em>6-methyladenosine (m6A) RNA modification has a role in cancer progression, including renal cell carcinomas (RCCs). Recent work showed that KIAA1429, which serves as a scaffold for the m6A methyltransferase holocomplex, is significantly upregulated in hepatocellular carcinoma tissues and presents oncogenic roles in breast and gastric cancers. However, the potential role of KIAA1429 in clear cell RCC and its underlying regulatory mechanism remain largely unknown.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730242</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730242-kiaa1429-myc-axis-is-potential-target-in-clear-cell-kidney-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-cancer-tumor.webp?t=1745263246" type="image/jpeg" medium="image" fileSize="344153">
        <media:title type="plain">Illustration of tumor on kidney</media:title>
      </media:content>
    </item>
    <item>
      <title>m6A modulates tumorigenicity, FTO inhibitor sensitivity in diffuse midline glioma</title>
      <description>
        <![CDATA[Understanding epi-transcriptome changes in diffuse midline gliomas H3 K27-altered (DMGs) could provide novel therapeutic options. RNA N6-methyladenosine (m6A) is a key epi-transcriptomic modification regulating RNA processes. A recently published study from the University of Sydney and collaborating institutions aimed to explore the m6A landscape in DMG.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730240</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730240-m6a-modulates-tumorigenicity-fto-inhibitor-sensitivity-in-diffuse-midline-glioma</link>
    </item>
    <item>
      <title>New China biotech Syneron chases macrocycle frontier</title>
      <description>
        <![CDATA[Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730152</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730152-new-china-biotech-syneron-chases-macrocycle-frontier</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Multicolor-peptide-illustration.webp?t=1775668991" type="image/jpeg" medium="image" fileSize="534333">
        <media:title type="plain">Multicolor peptide illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>UK formalizes zero tariffs deal with US, will pay more for drugs</title>
      <description>
        <![CDATA[The U.S. confirmed the agreement in principle made last December to exempt U.K. pharmaceuticals from import tariffs, as the U.K government put its commitment to spend more on patented drugs into effect.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730151</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730151-uk-formalizes-zero-tariffs-deal-with-us-will-pay-more-for-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/UK-USA-flags.webp?t=1718398728" type="image/jpeg" medium="image" fileSize="135783">
        <media:title type="plain">British and U.S. flags</media:title>
      </media:content>
    </item>
    <item>
      <title>Sidewinder’s bispecific ADC approach draws $137M series B</title>
      <description>
        <![CDATA[Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730148</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730148-sidewinders-bispecific-adc-approach-draws-137m-series-b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-digital-dollar-sign.webp?t=1775054521" type="image/jpeg" medium="image" fileSize="639573">
        <media:title type="plain">Blue digital dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Hengrui discovers new SNF2L2 inhibitors</title>
      <description>
        <![CDATA[A Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. patent describes new probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730202</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730202-hengrui-discovers-new-snf2l2-inhibitors</link>
    </item>
    <item>
      <title>CHNQD-01522 microtubule destabilizer demonstrates efficacy in HCC models</title>
      <description>
        <![CDATA[Researchers from Syngenta AG and collaborators reported the preclinical characterization of CHNQD-01522, a microtubule-targeting agent designed based on the marine natural product penipanoid C, in hepatocellular carcinoma (HCC) models.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730191</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730191-chnqd-01522-microtubule-destabilizer-demonstrates-efficacy-in-hcc-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/microtubule-structure-scientific-3D-render.webp?t=1775662264" type="image/jpeg" medium="image" fileSize="405330">
        <media:title type="plain">3D rendering of microtubule: Minus-end, GDP-lattice and GTP-cap at plus-end</media:title>
        <media:description type="plain">Scientific structure of microtubule.</media:description>
      </media:content>
    </item>
    <item>
      <title>Selective HPK1 inhibitor disclosed</title>
      <description>
        <![CDATA[Hematopoietic progenitor kinase 1 (HPK1) is a serine/threonine kinase primarily expressed in hematopoietic cells that functions as a negative regulator of immune cell signaling. Loss or inactivation of HPK1 enhances T-cell proliferation, cytokine secretion and overall antitumor immune responses.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730041</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730041-selective-hpk1-inhibitor-disclosed</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Test-tubes_dropper.webp?t=1588878275" type="image/png" medium="image" fileSize="371469">
        <media:title type="plain">Test tubes, dropper</media:title>
      </media:content>
    </item>
    <item>
      <title>Amplia halts enrollment in phase II pancreatic cancer trial </title>
      <description>
        <![CDATA[Amplia Therapeutics Ltd. has halted recruitment in its phase II Amplicity trial in advanced pancreatic cancer due to three dose-limiting toxicities related to the chemotherapy regimen, modified FOLFIRINOX (mFOLFIRINOX), which is being administered in combination with lead compound narmafotinib (AMP-945), a focal adhesion kinase inhibitor.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730134</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730134-amplia-halts-enrollment-in-phase-ii-pancreatic-cancer-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/pancreatic-cancer-pancreas-3D.webp?t=1729610305" type="image/jpeg" medium="image" fileSize="283423">
        <media:title type="plain">Illustration of cancer in the pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Gilead buying Tubulis and its ADCs in $5B takeover bid</title>
      <description>
        <![CDATA[German company Tubulis GmbH, which emerged with a $12.3 million series A round and a next-generation antibody-drug conjugate (ADC) platform about six years ago, has commanded up to $5 billion in a buyout offer from Gilead Sciences Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730133</guid>
      <pubDate>Tue, 07 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730133-gilead-buying-tubulis-and-its-adcs-in-5b-takeover-bid</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/ADC-illustration.webp?t=1763043550" type="image/jpeg" medium="image" fileSize="320648">
        <media:title type="plain">Antibody-drug conjugates floating on light purple background</media:title>
      </media:content>
    </item>
    <item>
      <title>Hematopoietic stem cell research points to leukemia’s early roots</title>
      <description>
        <![CDATA[Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference, held March 26, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730205</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730205-hematopoietic-stem-cell-research-points-to-leukemias-early-roots</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells.webp?t=1588880225" type="image/png" medium="image" fileSize="554020">
        <media:title type="plain">Cancer and blood cells</media:title>
      </media:content>
    </item>
  </channel>
</rss>
